Velkommen til Dansk Myelomatose Forenings hjemmeside › Fora › Debat › Behandling i udlandet › Svar til: Behandling i udlandet
Dette ser også meget interessant ud http://myeloma.org/PortalPage.action?tabId=8&menuId=366&portalPageId=18
“Understanding that the search for a cure for multiple myeloma demands constant innovation, the IMF has launched the Black Swan Research Initiative® (BSRI®), a unique project to develop the first definitive cure for myeloma.
Through medical innovation we can already achieve long-term complete remissions in 15 to 20 percent of myeloma patients. Now, by identifying the best treatments at the best time to achieve the best objective, we’re ready to bridge the gap from long-term remission to cure.”
Der tales her om kurativt sigte, og det er et af de første steder jeg har læst om noget sådant.
“Introducing the IMF’s Black Swan Research Initiative®
Understanding that the search for a cure for multiple myeloma demands constant innovation, the IMF has launched the Black Swan Research Initiatve®, a unique project to develop the first definitive cure for myeloma. Led by a multinational consortium of leading myeloma experts, we are bridging the gap from long-term remission to cure.”
Og der fortsættes:
“What is Minimal Residual Disease (MRD)?
When a patient is diagnosed with multiple myeloma, conventional wisdom thinks of it as one disease when in reality there are multiple diseases in one. There are many clones of multiple myeloma cells that are present in the same patient. Current treatments for myeloma target the dominant clones, but often leave behind some of the more resistant clones, which may lead to relapse down the line. These leftover cells are the Minimal Residual Disease, or MRD.
Defining the Cure: MRD-Zero™
Cancer cures are predominantly defined by waiting a fixed number of years post-remission to see if any cancerous cells emerge. Now, with a new understanding of myeloma at the molecular level, the IMF’s Black Swan Research Initiative is developing ultra-sensitive tests to accurately measure Minimal Residual Disease and define its absence as a cure.”
Håber at kunne høre de danske hæmatologers vurdering af disse initiativer.
Jeg dukker ihvertfald op til temadag i Roskilde d. 20/9: http://www.myelomatose.dk/blog/indbydelse-til-temadage/